The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Matt Hewitt - Craig-Hallum - Analyst
: Good afternoon, gentlemen, and congratulations on the strong quarter.
Question: Matt Hewitt - Craig-Hallum - Analyst
: My first one, obviously, on everybody's mind, I'm just curious what impact, if any, are you seeing from coronavirus? Maybe how is that impacting
the start times from some studies or anything along those lines?
Question: Matt Hewitt - Craig-Hallum - Analyst
: Along those lines, I had seen some articles talking about the -- I think it's -- correct me if I'm wrong, but the ACE2 mice and how those are in very
short supply. I don't -- correct me if I'm wrong, but I don't think you guys work with those types of mice, correct?
Question: Matt Hewitt - Craig-Hallum - Analyst
: Okay. All right. Well, thank you for the color on the virus. I guess shifting gears a little bit, you commented in the press release and then in your
prepared remarks regarding adding to the sales and business -- biz dev headcount. Where does that sit now and where do you see that going over
the next year?
Question: Matt Hewitt - Craig-Hallum - Analyst
: Got it. Okay. And then maybe last one and I'll hop back into queue. Thank you for the update on flow cytometry and the incremental color that
you provided as far as some of those pharma customers have come in, inspected, you're now on their approved list.
Any additional color that you could provide as far as how frequently are those types of opportunities coming up for bid? Do you have any sense
for how frequently that occurs? And when -- I know it's difficult, but when you might anticipate seeing some contracts being signed there? Thank
you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 12, 2020 / NTS, CSBR.OQ - Q3 2020 Champions Oncology Inc Earnings Call
Question: Matt Hewitt - Craig-Hallum - Analyst
: Understood. Thank you.
Question: Matt Hewitt - Craig-Hallum - Analyst
: I'll keep going. As far as -- there was a mention of a small bad debt, nonrecurring bad debt write-off. What was the amount of that during the
quarter, David?
Question: Matt Hewitt - Craig-Hallum - Analyst
: $150,000, okay. That's great. And then I guess the last piece here regarding -- as you add these new services and new market opportunities and
you're adding some salespeople, how quickly are those new services translating into bookings and revenues? Is that -- are you able to flip the
switch on those pretty quickly? Or do they require some lead time, maybe not to the extent of flow, but maybe they require a couple of quarters
before those orders start to flow?
Question: Matt Hewitt - Craig-Hallum - Analyst
: Understood. All right. Well, thank you for that color.
| 
